Engel Law PLLC is investigating whether fair value to Amryt shareholders will result from the proposed sale of Amryt Pharma Plc (NASDAQ: AMYT) to Chiesi Farmaceutici S.p.A. for $14.50 per ADS, plus Contingent Value Rights of up to an additional $2.50 per ADS.
The Firm’s investigation concerns:
(i) whether Amryt’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration ($14.50 per ADS, plus Contingent Value Rights of up to an additional $2.50 per ADS) adequately compensates Amryt’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.